NCT04849416 2026-02-06
A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)
Eli Lilly and Company
Phase 2 Completed
Eli Lilly and Company
University of Utah
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute